肺切除术后早期经鼻高流量氧疗与文丘里面罩氧疗对比:一项随机试验
这项在意大利教学医院开展的单中心随机试验纳入96例开胸肺切除术后拔管的成人患者,比较经鼻高流量氧疗与文丘里面罩氧疗持续2天对术后4天内低氧血症(PaO2/FiO2<300 mmHg)发生率的影响。两组低氧血症发生率无差异(高流量组81% vs 文丘里面罩组79%,未调整OR 1.11,95%CI 0.41-3,p=0.84),呼吸困难程度、停氧后需氧疗比例、肺部并发症及需呼吸支持比例亦无组间差异。事后分析显示两组PaO2/FiO2无差异(p=0.92),但高流量组动脉二氧化碳分压更低(组间平均差2 mmHg,95%CI 0.5-3.4,p=0.009),术后高碳酸血症风险更低(调整OR 0.18,95%CI 0.06-0.54,p=0.002)。作者认为需进一步开展足够把握度的研究明确高流量氧疗对二氧化碳清除的临床获益。
要点
- 开胸肺切除术后预防性经鼻高流量氧疗未降低术后4天内低氧血症发生率:高流量组81% vs 文丘里面罩组79%,未调整OR 1.11(95%CI 0.41-3),p=0.84。
- 事后分析显示高流量组动脉二氧化碳分压较文丘里面罩组低,组间平均差2 mmHg(95%CI 0.5-3.4),p=0.009。
- 高流量组术后高碳酸血症风险更低:调整OR 0.18(95%CI 0.06-0.54),p=0.002。
- 两组在呼吸困难程度、停氧后需氧疗比例(OR 1.34,95%CI 0.60-3)、肺部并发症(OR 1.29,95%CI 0.51-3.25)及需呼吸支持(OR 0.67,95%CI 0.11-4.18)方面无差异。
- 研究期间两组PaO2/FiO2无差异(p=0.92)。
适用人群与场景
- 意大利一家教学医院连续纳入的接受开胸肺切除术的成人患者,排除长期氧疗者。
- 术后拔管后入住重症监护环境(由原文「after extubation」及术后氧疗场景推断,原文未明确病房类型)。
诊断标准与关键阈值
- 术后低氧血症定义:PaO2/FiO2低于300 mmHg(术后4天内)。
处置流程与药物剂量
- 拔管后随机接受经鼻高流量氧疗或文丘里面罩氧疗,持续2个术后日。
- 术后高碳酸血症为事后分析指标,原文未给出其定义阈值。
研究设计与关键结果
- 单中心随机试验,2015年9月至2018年4月纳入96例,分析95例(高流量组47例,文丘里面罩组48例)。
- 主要终点术后4天内低氧血症发生率:高流量组38例(81%)vs 文丘里面罩组38例(79%),未调整OR 1.11(95%CI 0.41-3),p=0.84。
- 停氧后需氧疗比例OR 1.34(95%CI 0.60-3);肺部并发症OR 1.29(95%CI 0.51-3.25);需呼吸支持OR 0.67(95%CI 0.11-4.18)。
- 事后分析:研究期间PaO2/FiO2组间无差异(p=0.92);高流量组动脉二氧化碳分压更低,组间平均差2 mmHg(95%CI 0.5-3.4),p=0.009;术后高碳酸血症调整OR 0.18(95%CI 0.06-0.54),p=0.002。
证据类型、等级与局限
- 证据类型:单中心随机对照试验。
- 试验注册号:ClinicalTrials.gov NCT02544477,注册日期2015年9月9日。
- 局限:原文报告需进一步开展足够把握度的研究以明确高流量氧疗对二氧化碳清除的临床获益。
对床旁实践的改变
- 作者认为,与文丘里面罩相比,开胸肺切除术后预防性经鼻高流量氧疗未降低术后低氧血症发生率,也未改善其他分析结局。
- 作者认为,需进一步开展足够把握度的研究,以明确经鼻高流量氧疗是否对二氧化碳清除产生临床获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Data on high-flow nasal oxygen after thoracic surgery are limited and confined to the comparison with low-flow oxygen. Different from low-flow oxygen, Venturi masks provide higher gas flow at a predetermined fraction of inspired oxygen (FiO2). We conducted a randomized trial to determine whether preemptive high-flow nasal oxygen reduces the incidence of postoperative hypoxemia after lung resection, as compared to Venturi mask oxygen therapy.
METHODS: In this single-center, randomized trial conducted in a teaching hospital in Italy, consecutive adult patients undergoing thoracotomic lung resection, who were not on long-term oxygen therapy, were randomly assigned to receive high-flow nasal or Venturi mask oxygen after extubation continuously for two postoperative days. The primary outcome was the incidence of postoperative hypoxemia (i.e., ratio of the partial pressure of arterial oxygen to FiO2 (PaO2/FiO2) lower than 300 mmHg) within four postoperative days.
RESULTS: Between September 2015 and April 2018, 96 patients were enrolled; 95 patients were analyzed (47 in high-flow group and 48 in Venturi mask group). In both groups, 38 patients (81% in the high-flow group and 79% in the Venturi mask group) developed postoperative hypoxemia, with an unadjusted odds ratio (OR) for the high-flow group of 1.11 [95% confidence interval (CI) 0.41-3] (p = 0.84). No inter-group differences were found in the degree of dyspnea nor in the proportion of patients needing oxygen therapy after treatment discontinuation (OR 1.34 [95% CI 0.60-3]), experiencing pulmonary complications (OR 1.29 [95% CI 0.51-3.25]) or requiring ventilatory support (OR 0.67 [95% CI 0.11-4.18]). Post hoc analyses revealed that PaO2/FiO2 during the study was not different between groups (p = 0.92), but patients receiving high-flow nasal oxygen had lower arterial pressure of carbon dioxide, with a mean inter-group difference of 2 mmHg [95% CI 0.5-3.4] (p = 0.009), and were burdened by a lower risk of postoperative hypercapnia (adjusted OR 0.18 [95% CI 0.06-0.54], p = 0.002).
CONCLUSIONS: When compared to Venturi mask after thoracotomic lung resection, preemptive high-flow nasal oxygen did not reduce the incidence of postoperative hypoxemia nor improved other analyzed outcomes. Further adequately powered investigations in this setting are warranted to establish whether high-flow nasal oxygen may yield clinical benefit on carbon dioxide clearance.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT02544477 . Registered 9 September 2015.
参考来源
- Pennisi MA, Bello G, Congedo MT, et al. Early nasal high-flow versus Venturi mask oxygen therapy after lung resection: a randomized trial. Crit Care. 2019. PMID: 30819227. doi:10.1186/s13054-019-2361-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。